-+ 0.00%
-+ 0.00%
-+ 0.00%

SAVARA RESUBMITS THE BIOLOGICS LICENSE APPLICATION (BLA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR MOLBREEVI* FOR THE POTENTIAL TREATMENT OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP)

Reuters·12/22/2025 13:30:01

Please log in to view news